Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

NCT02180217 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushings Disease

Interventions

DRUG: osilodrostat
DRUG: LCI699 matching placebo

Sponsor

Novartis Pharmaceuticals